LLL12 is a STAT3 small molecule inhibitor that can suppress STAT3 phosphorylation. LLL12 enhances the inhibitory activities of cisplatin and paclitaxel on ovarian cancer/tumor cell generation, migration, and growth.

Physicochemical Properties

Molecular Formula	C14H9NO5S
Molecular Weight	303.29
Exact Mass	303.02
CAS #	1260247-42-4
PubChem CID	46911017
Appearance	Light yellow to yellow solid powder
LogP	2.596
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	6
Rotatable Bond Count	1
Heavy Atom Count	21
Complexity	566
Defined Atom Stereocenter Count	0
InChi Key	CQBHSRLUQDYPBU-UHFFFAOYSA-N
InChi Code	InChI=1S/C14H9NO5S/c15-21(19,20)10-6-2-4-8-12(10)14(18)7-3-1-5-9(16)11(7)13(8)17/h1-6,16H,(H2,15,19,20)
Chemical Name	5-hydroxy-9,10-dioxoanthracene-1-sulfonamide
Synonyms	LLL 12; LLL-12; LLL12
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage.
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

ln Vitro	Cardiovascular cell viability can be inhibited by LLL12 (0.01-1 μM; 72 h) in response to cisplatin (0.5 μM, 2.5 μM) and paclitaxel (0.25 μM, 0.5 μM) [1].
ln Vivo	In mouse osteosarcoma cell and tumor growth, LLL12 (5 mg/kg; intraperitoneal injection; once daily for 13 days) demonstrates potent growth inhibitory action [2].
Cell Assay	Western blot analysis [1] Cell Types: A2780, SKOV3, CAOV-3 and OVCAR5 ovarian cancer cell lines Tested Concentrations: 0.25, 0.5 and 1 μM μM) Phosphorylation of STAT3 (Tyr705) in fluorescently labeled dye lines [1]. A2780 and OVCAR5; SKOV3 and CAOV-3 at 1, 2.5 and 5 μM respectively. Incubation Duration: 72 hrs (hours). Experimental Results: Inhibition of STAT3 phosphorylation at Tyr705.
Animal Protocol	Animal/Disease Models: Mouse xenograft SJSA or OS-33 osteosarcoma cells [2] Doses: 5 mg/kg Route of Administration: intraperitoneal (ip) injection; one time/day for 13 days Experimental Results: Result in OS-33 and SJSA xenograft mice Tumor volume and tumor mass were Dramatically diminished.
References	[1]. A small molecule STAT3 inhibitor, LLL12, enhances cisplatin‑ and paclitaxel‑mediated inhibition of cell growth and migration in human ovarian cancer cells. Oncol Rep. 2020 Sep;44(3):1224-1232. [2]. Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice. Invest New Drugs. 2012 Jun;30(3):916-26.

Solubility Data

Solubility (In Vitro)	DMSO : ~100 mg/mL (~329.72 mM)
Solubility (In Vivo)	Solubility in Formulation 1: 0.5 mg/mL (1.65 mM) in 2% DMSO + 40% PEG300 +5% Tween-80 + 53% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	3.2972 mL	16.4859 mL	32.9717 mL
	5 mM	0.6594 mL	3.2972 mL	6.5943 mL
	10 mM	0.3297 mL	1.6486 mL	3.2972 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.